Literature DB >> 24629344

The treatment-naive microbiome in new-onset Crohn's disease.

Subra Kugathasan1, Lee A Denson2, Dirk Gevers3, Yoshiki Vázquez-Baeza4, Will Van Treuren5, Boyu Ren6, Emma Schwager6, Dan Knights7,8, Se Jin Song5, Moran Yassour3, Xochitl C Morgan6, Aleksandar D Kostic3, Chengwei Luo3, Antonio González5, Daniel McDonald5, Yael Haberman2, Thomas Walters9, Susan Baker10, Joel Rosh11, Michael Stephens12, Melvin Heyman13, James Markowitz14, Robert Baldassano15, Anne Griffiths16, Francisco Sylvester17, David Mack18, Sandra Kim19, Wallace Crandall19, Jeffrey Hyams17, Curtis Huttenhower3,6, Rob Knight5,20,21, Ramnik J Xavier3,22,23.   

Abstract

Inflammatory bowel diseases (IBDs), including Crohn's disease (CD), are genetically linked to host pathways that implicate an underlying role for aberrant immune responses to intestinal microbiota. However, patterns of gut microbiome dysbiosis in IBD patients are inconsistent among published studies. Using samples from multiple gastrointestinal locations collected prior to treatment in new-onset cases, we studied the microbiome in the largest pediatric CD cohort to date. An axis defined by an increased abundance in bacteria which include Enterobacteriaceae, Pasteurellacaea, Veillonellaceae, and Fusobacteriaceae, and decreased abundance in Erysipelotrichales, Bacteroidales, and Clostridiales, correlates strongly with disease status. Microbiome comparison between CD patients with and without antibiotic exposure indicates that antibiotic use amplifies the microbial dysbiosis associated with CD. Comparing the microbial signatures between the ileum, the rectum, and fecal samples indicates that at this early stage of disease, assessing the rectal mucosal-associated microbiome offers unique potential for convenient and early diagnosis of CD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24629344      PMCID: PMC4059512          DOI: 10.1016/j.chom.2014.02.005

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  42 in total

1.  Abundance-based similarity indices and their estimation when there are unseen species in samples.

Authors:  Anne Chao; Robin L Chazdon; Robert K Colwell; Tsung-Jen Shen
Journal:  Biometrics       Date:  2006-06       Impact factor: 2.571

2.  Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats.

Authors:  H C Rath; H H Herfarth; J S Ikeda; W B Grenther; T E Hamm; E Balish; J D Taurog; R E Hammer; K H Wilson; R B Sartor
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

3.  Development and validation of a pediatric Crohn's disease activity index.

Authors:  J S Hyams; G D Ferry; F S Mandel; J D Gryboski; P M Kibort; B S Kirschner; A M Griffiths; A J Katz; R J Grand; J T Boyle
Journal:  J Pediatr Gastroenterol Nutr       Date:  1991-05       Impact factor: 2.839

Review 4.  Adherent-invasive Escherichia coli in inflammatory bowel disease.

Authors:  Nathalie Rolhion; Arlette Darfeuille-Michaud
Journal:  Inflamm Bowel Dis       Date:  2007-10       Impact factor: 5.325

5.  Phospholipid turnover in the inflamed intestinal mucosa: arachidonic acid-rich phosphatidyl/plasmenyl-ethanolamine in the mucosa in inflammatory bowel disease.

Authors:  H Morita; K Nakanishi; T Dohi; E Yasugi; M Oshima
Journal:  J Gastroenterol       Date:  1999-02       Impact factor: 7.527

6.  Influence of dietary catechols on the growth of enteropathogenic bacteria.

Authors:  Primrose P E Freestone; Nicholas J Walton; Richard D Haigh; Mark Lyte
Journal:  Int J Food Microbiol       Date:  2007-08-01       Impact factor: 5.277

Review 7.  Diet and inflammatory bowel disease: review of patient-targeted recommendations.

Authors:  Jason K Hou; Dale Lee; James Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-06       Impact factor: 11.382

8.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.

Authors:  Harry Sokol; Bénédicte Pigneur; Laurie Watterlot; Omar Lakhdari; Luis G Bermúdez-Humarán; Jean-Jacques Gratadoux; Sébastien Blugeon; Chantal Bridonneau; Jean-Pierre Furet; Gérard Corthier; Corinne Grangette; Nadia Vasquez; Philippe Pochart; Germain Trugnan; Ginette Thomas; Hervé M Blottière; Joël Doré; Philippe Marteau; Philippe Seksik; Philippe Langella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

9.  Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers.

Authors:  Heba S Said; Wataru Suda; Shigeki Nakagome; Hiroshi Chinen; Kenshiro Oshima; Sangwan Kim; Ryosuke Kimura; Atsushi Iraha; Hajime Ishida; Jiro Fujita; Shuhei Mano; Hidetoshi Morita; Taeko Dohi; Hiroki Oota; Masahira Hattori
Journal:  DNA Res       Date:  2013-09-07       Impact factor: 4.458

10.  The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing.

Authors:  Les Dethlefsen; Sue Huse; Mitchell L Sogin; David A Relman
Journal:  PLoS Biol       Date:  2008-11-18       Impact factor: 8.029

View more
  1053 in total

Review 1.  The gut microbiome in health and in disease.

Authors:  Andrew B Shreiner; John Y Kao; Vincent B Young
Journal:  Curr Opin Gastroenterol       Date:  2015-01       Impact factor: 3.287

Review 2.  Dysbiosis and the immune system.

Authors:  Maayan Levy; Aleksandra A Kolodziejczyk; Christoph A Thaiss; Eran Elinav
Journal:  Nat Rev Immunol       Date:  2017-03-06       Impact factor: 53.106

3.  Metabolic labeling puts the microbiome under the microscope.

Authors:  Graham J Britton; Jeremiah J Faith
Journal:  Nat Med       Date:  2015-09       Impact factor: 53.440

Review 4.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11

5.  Captivity humanizes the primate microbiome.

Authors:  Jonathan B Clayton; Pajau Vangay; Hu Huang; Tonya Ward; Benjamin M Hillmann; Gabriel A Al-Ghalith; Dominic A Travis; Ha Thang Long; Bui Van Tuan; Vo Van Minh; Francis Cabana; Tilo Nadler; Barbara Toddes; Tami Murphy; Kenneth E Glander; Timothy J Johnson; Dan Knights
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

Review 6.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

7.  The gut commensal Bacteroides thetaiotaomicron exacerbates enteric infection through modification of the metabolic landscape.

Authors:  Meredith M Curtis; Zeping Hu; Claire Klimko; Sanjeev Narayanan; Ralph Deberardinis; Vanessa Sperandio
Journal:  Cell Host Microbe       Date:  2014-12-10       Impact factor: 21.023

8.  Paneth cell defects in Crohn's disease patients promote dysbiosis.

Authors:  Ta-Chiang Liu; Bhaskar Gurram; Megan T Baldridge; Richard Head; Vy Lam; Chengwei Luo; Yumei Cao; Pippa Simpson; Michael Hayward; Mary L Holtz; Pavlos Bousounis; Joshua Noe; Diana Lerner; Jose Cabrera; Vincent Biank; Michael Stephens; Curtis Huttenhower; Dermot Pb McGovern; Ramnik J Xavier; Thaddeus S Stappenbeck; Nita H Salzman
Journal:  JCI Insight       Date:  2016-06-02

9.  High throughput sequencing reveals distinct microbial populations within the mucosal and luminal niches in healthy individuals.

Authors:  Yehuda Ringel; Nitsan Maharshak; Tamar Ringel-Kulka; Elizabeth Ashley Wolber; R Balfour Sartor; Ian M Carroll
Journal:  Gut Microbes       Date:  2015

10.  Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype.

Authors:  Leopoldo N Segal; Jose C Clemente; Jun-Chieh J Tsay; Sergei B Koralov; Brian C Keller; Benjamin G Wu; Yonghua Li; Nan Shen; Elodie Ghedin; Alison Morris; Phillip Diaz; Laurence Huang; William R Wikoff; Carles Ubeda; Alejandro Artacho; William N Rom; Daniel H Sterman; Ronald G Collman; Martin J Blaser; Michael D Weiden
Journal:  Nat Microbiol       Date:  2016-04-04       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.